Thomas E. Olencki
Impact in
- Oncology top 1%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Pancreatic and Hepatic Oncology Research
-
- Renal cell carcinoma treatment
Papers in
- Oncology 53
- Cancer Immunotherapy and Biomarkers 18
- CAR-T cell therapy research 10
- Pancreatic and Hepatic Oncology Research 7
- Cutaneous Melanoma Detection and Management 5
-
- Renal cell carcinoma treatment 21
- Co-authors
- Ronald M. Bukowski (43 shared papers)Toni K. Choueiri (8 shared papers)Meghara K. Walsh (4 shared papers)Susan Halabi (4 shared papers)Eric Jay Small (4 shared papers)M. Morris (4 shared papers)Marc Dror Michaelson (4 shared papers)Joel Picus (4 shared papers)
- Journals
- Journal of Immunotherapy (9 papers)Annals of Oncology (7 papers)Investigational New Drugs (6 papers)Cancer (6 papers)Journal of Clinical Oncology (5 papers)
- Partner nations
- United StatesSwitzerlandIndia
In The Last Decade
Thomas E. Olencki
102 papers receiving 4.0k citations
Thomas E. Olencki's Hit Papers
Peers
Comparison fields: 5 of 104
- Oncology 1.7k
- Pulmonary and Respiratory Medicine 1.7k
- Cancer Research 613
- Immunology 807
- Molecular Biology 1.2k
Countries citing papers authored by Thomas E. Olencki
This map shows the geographic impact of Thomas E. Olencki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas E. Olencki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas E. Olencki more than expected).
Fields of papers citing papers by Thomas E. Olencki
This network shows the impact of papers produced by Thomas E. Olencki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas E. Olencki. The network helps show where Thomas E. Olencki may publish in the future.
Co-authors
The 25 scholars most cited alongside Thomas E. Olencki, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 106 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial Hit paper breakdown → | 2017 | 553 |
| 2 | 2014 | 386 | |
| 3 | Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial Hit paper breakdown → | 2018 | 291 |
| 4 | Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update Hit paper breakdown → | 2018 | 290 |
| 5 | Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. | 1998 | 205 |
| 6 | 2003 | 154 | |
| 7 | 2018 | 126 | |
| 8 | A Global Review of Melanoma Follow-up Guidelines. | 2013 | 122 |
| 9 | 2015 | 122 | |
| 10 | 2011 | 104 | |
| 11 | 2016 | 97 | |
| 12 | 1995 | 83 | |
| 13 | 2017 | 83 | |
| 14 | 2017 | 81 | |
| 15 | 2019 | 81 | |
| 16 | 2016 | 62 | |
| 17 | 2004 | 61 | |
| 18 | 2003 | 59 | |
| 19 | Signal transduction abnormalities in T lymphocytes from patients with advanced renal carcinoma: clinical relevance and effects of cytokine therapy. | 1998 | 57 |
| 20 | 1997 | 46 |
About Thomas E. Olencki
Thomas E. Olencki is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Immunology, Molecular Biology and Hematology, having authored 106 papers that have together received 4.1k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (21 papers), Cancer Immunotherapy and Biomarkers (18 papers), Immunotherapy and Immune Responses (11 papers), CAR-T cell therapy research (10 papers), Nonmelanoma Skin Cancer Studies (8 papers), Pancreatic and Hepatic Oncology Research (7 papers), Melanoma and MAPK Pathways (7 papers) and Cutaneous Melanoma Detection and Management (5 papers). The work is most often cited by research in Oncology (1.7k citations), Pulmonary and Respiratory Medicine (1.7k citations), Cancer Research (613 citations), Immunology (807 citations) and Molecular Biology (1.2k citations). Thomas E. Olencki has collaborated with scholars based in United States, Switzerland and India. Frequent co-authors include Ronald M. Bukowski, Toni K. Choueiri, Meghara K. Walsh, Susan Halabi, Eric Jay Small, M. Morris, Marc Dror Michaelson, Joel Picus, Shaker R. Dakhil and Olwen Mary Hahn. Their work appears in journals such as Journal of Immunotherapy, Annals of Oncology, Investigational New Drugs, Cancer and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.